Key result
Trifecta, INTUITY, and Perceval bioprostheses yield similar clinical outcomes in elderly patients with small annuli.
Why the study?
Aortic valve replacement in elderly patients with small aortic annulus is challenging due to technical aspects and high risk of patient-prosthesis mismatch, and the ideal prosthesis has yet to be identified.
Do different bioprostheses (Trifecta, Edwards INTUITY Elite, Perceval) yield different clinical and hemodynamic outcomes in elderly patients with severe aortic stenosis and small aortic annuli?
Cohort (n=76)
Yes
Do different bioprostheses (Trifecta, Edwards INTUITY Elite, Perceval) yield different clinical and hemodynamic outcomes in elderly patients with severe aortic stenosis and small aortic annuli?
p-value: p=0.04 and 0.01
In elderly patients with small aortic annuli, Trifecta, Edwards INTUITY Elite, and Perceval bioprostheses all provide reliable clinical outcomes and LV mass regression, despite higher postoperative pressure gradients with the Trifecta valve.
Supports valve choice flexibility in elderly small-annuli patients; leaves open long-term durability questions in this observational cohort.
OBJECTIVES: Aortic valve replacement (AVR) in patients with small aortic annulus (diameter ≤21 mm) is considered a challenging scenario because of technical aspects and the high risk of patient-prosthesis mismatch (PPM). The choice of the appropriate prosthesis is crucial, and at the moment, an ideal device has yet to be identified. We compare clinical and hemodynamic results after AVR with three bioprostheses with different design and characteristics. METHODS: We retrospectively evaluated 76 consecutive patients from two cardiac surgery centers who underwent AVR (Trifecta = 24; Edwards INTUITY Elite valve system = 26, and Perceval = 26) for severe aortic stenosis between 2013 and 2017. Patients selected were older than 75 years and with an annulus diameter ≤21 mm at preoperative echocardiogram. Reinterventions and combined procedures were excluded. Minimally invasive AVR was performed in 44 (57.8%) patients. Telephonic interview was obtained at 2.9 ± 0.5 years and echocardiographic follow-up at 2.2 ± 0.8 years. RESULTS: Clinical outcome was similar in the three groups. At follow-up, Trifecta patients presented significantly higher peak and mean transprosthetic pressure gradients ( P = 0.04 and 0.01). Effective orifice area and left ventricular mass regression were comparable, although an advantage was observed in Perceval patients without reaching the statistical significance. Incidence of moderate ( P = 0.2) and severe PPM ( P = 0.7) was comparable. CONCLUSIONS: Despite higher postoperative pressure gradients observed with the Trifecta valve, all three prostheses (Trifecta, Edwards INTUITY Elite, and Perceval) have proven to be reliable when implanted in small aortic annuli, with good clinical outcome and favorable left ventricular mass regression.
No takes yet. Share an insight, caveat, or question.
Chiariello et al. (2019) conducted a cohort in severe aortic stenosis (n=76). Trifecta, Edwards INTUITY Elite, and Perceval bioprostheses vs. Compared against each other was evaluated on Clinical outcome and hemodynamic results (peak and mean transprosthetic pressure gradients) (p=0.04 and 0.01). Aortic valve replacement with Trifecta, Edwards INTUITY Elite, and Perceval bioprostheses provided similar clinical outcomes in elderly patients with small annuli, despite higher pressure gradients with Trifecta (P=0.04 and 0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: